Key facts
- This page summarizes Jeffrey L. Wade's Form 4 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 08 Jul 2024, 17:27.
Jeffrey L. Wade - 08 Jul 2024 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)
- Reporting relationship
- President and COO
- Issuer ticker
- LXRX
- Reported as of
- 08 Jul 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 08 Jul 2024, 17:27:46 UTC
- Prior SEC filing
- 29 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeffrey L. Wade
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jeffrey L. Wade filed Form 4 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 08 Jul 2024.
Change
- Previous filing in this sequence was filed on 29 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LXRX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +307,000
- Change %
- Price
- $0.000000
- Shares after
- 307,000
- Date
- 08 Jul 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 307,000
- Exercise price
- $1.67
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.